Home > Boards > US OTC > Medical - Drugs >

OncBioMune Pharmaceuticals Inc. (OBMP)

OBMP RSS Feed
Add OBMP Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, Weedman1
Search This Board: 
Last Post: 5/19/2019 9:17:05 AM - Followers: 108 - Board type: Free - Posts Today: 1

Image result for biotech

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane).


 





Press releases: http://oncbiomune.com/news/

SEC Filings: https://www.sec.gov/cgi-bin/browse-edgar?company=oncbiomune&owner=exclude&action=getcompany

Quote: https://www.otcmarkets.com/stock/OBMP/overview

Clinical trials: 
 https://clinicaltrials.gov/ct2/results?cond=&term=oncbiomune&cntry=&state=&city=&dist=





CHIEF LEADERSHIP

 

Image result for Dr. Jonathan Head

Dr. Jonathan Head, Ph.D.

 

Dr. Jonathan Head, Ph.D.

 
 

CHAIRMAN OF THE BOARD, CHIEF SCIENTIFIC OFFICER

Dr. Head has been instrumental in the development of our new chemotherapy and immunotherapy programs. Dr. Head is a co-developer and patent holders of one of the first patented autologous breast cancer vaccines in the United States.  His major goal is to implement translational research – the movement of laboratory-developed technologies into the clinical setting.  This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.

As a tumor cell biologist, Dr. Head’s specialties include:

  • Cell culture research
    Animal research
    Human clinical research
    Innovative chemotherapies
    Immunotherapy/cancer vaccines
    Oncogene and antisense research
    Tumor markers

Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine.   He is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology.

 
 
Dr. Brian Barnett

Dr. Brian Barnett, M.D.

 
 

CHIEF EXECUTIVE OFFICER

Prior to joining OncBioMune, Dr. Barnett served at Puma Biotechnology, Inc. since August 2016  most recently as a Vice President and Head of Medical Affairs. Prior to his time with Puma, Dr. Barnett was with Genentech, Inc., a subsidiary of Roche, from October 2012 to August 2016 and served as Medical Director, Kadcyla (T-DM1), Global Product Development Oncology and U.S. Medical Affairs.

Prior to his appointment as CEO, Dr. Barnett was a member of the Company’s Scientific Advisory Board. Dr. Barnett received his B.S. from Millsaps College, M.D. from the University of Mississippi Medical Center, and completed his Medical Oncology Fellowship at Tulane University in New Orleans.

 



 

Andrew Kucharchuk
 

CHIEF FINANCIAL OFFICER, PRESIDENT, DIRECTOR

Andrew “Al” Kucharchuk is a graduate of Louisiana State and Tulane Universities Freeman School of Business, where he earned an MBA with a Finance Concentration. He currently serves as the Company’s Chief Financial Officer and oversees the business and administrative processes.  In addition to these duties, Al also directs business development efforts including the expansion of operations to accommodate increased research and clinical development. Al has assisted Dr. Head in the administration of the three contracts that have lead to the clinical studies for the Company’s lead product, ProscaVax™.

Mr. Kucharchuk is a member of Kappa Alpha Order fraternity. He lives in Baton Rouge with his wife Jessica and their sons Henry and Davis.

 
 

Robert Neal Holcomb

 
 

DIRECTOR

Mr. Holcomb earned his Bachelor of Business Administration degree from Delta State University (DSU) in 1992.  He is a Certified Public Accountant and is the president and owner of Holcomb CPA Firm, P.A. in Rolling Fork, MS since 2005.  Prior to OncBioMune coming public, Mr. Holcomb was the company’s CPA, making him very familiar with the complete pipeline of drug candidates.  He also currently serves as both an officer and board member of several private companies.

After losing both parents to cancer, Neal had a burning desire to fight cancer. In 1999, Neal was a founding member the MS Breast Foundation.  The MS Breast Foundation provides extensive funding for cancer research through many cancer organizations.  He has been president and executive director of the MS Breast Foundation since 2003.

Neal is a major contributor to his college alma mater in Cleveland, MS.  He has made many accomplishments and has won awards, such as the Hugh Ellis Walker Alumni Service Award for outstanding service and contributions to DSU by an alumnus and the Robert L. and Mary C. Elliott Delta State University Inspiration Award for dedication to students in reaching their academic potential.

Neal has been married to Dr. Kyla M. Holcomb for 25 years.  They have two children, Shelby Grace and Richard Walker and currently reside in Glen Allan, MS on Lake Washington.
 


 

 

Charles L. Rice, Jr.

 
DIRECTOR

Mr. Rice is the President and Chief Executive Officer of Entergy New Orleans, Inc., an $800 million a year electric and gas utility and subsidiary of NYSE-listed Entergy Corporation.  After his first legal private practice position in Louisiana with Jones, Walker, Waechter, Poitevent, Carrere & Denegre, L.L.P, Rice joined Entergy in the legal department in 2000, serving as senior counsel in the Entergy Services, Inc. litigation group and then as manager of labor relations litigation support in human resources.

Rice was recruited into New Orleans city government in 2002 as the city attorney and later took the critical role of chief administrative officer for the City of New Orleans, where he managed 6,000 employees and the city’s $600 million budget. In 2005, the law firm of Barrasso, Usdin, Kupperman, Freeman & Sarver, L.L.C. recruited him back to private practice, where he was named partner.

Returning to Entergy in 2009, Rice served as director of utility strategy where he was responsible for coordinating regulatory, legislative, and communications efforts to develop and execute strategies that advanced commercial objectives for the company’s regulated service areas. He then served as director of regulatory affairs for Entergy New Orleans.

Rice holds a bachelor’s degree in business administration from Howard University, a juris doctorate from Loyola University’s School of Law and master’s degree in business administration from Tulane University. After graduating from Howard University, he was commissioned as a second lieutenant in the United States Army and served as a military intelligence officer with the 101st Airborne Division (Air Assault) at Fort Campbell, KY. While in the Army, he earned the Airborne Badge, Air Assault badge and was awarded the Army Commendation and the Army Achievement medals.

He is a member of the Alabama and Louisiana State Bar Associations, the American Bar Association, the New Orleans Bar Association, and the National Bar Association.

 
 

Daniel Hoverman


DIRECTOR

Daniel Hoverman is a Director at NYSE-listed Houlihan Lokey, a leading global investment bank, where he is a senior member of the firm’s Corporate Finance Group. Mr. Hoverman is also actively involved with Houlihan Lokey’s efforts in equity capital markets.

Mr. Hoverman has extensive mergers and acquisitions advisory and financing experience, having completed over $100 billion of transactions for both private and public companies across multiple industries and geographies. Before joining Houlihan Lokey, he was a Director with Credit Suisse in Hong Kong as a member of the office of the General Counsel, and was responsible for oversight and management of investment banking transactions. Prior to Credit Suisse, he was a Director with UBS Investment Bank in New York as a member of the firm’s Equity Capital Markets Group and Equity Corporate Finance Team, where he was responsible for origination, oversight and management of securities offerings. He began his career with Kirkland & Ellis LLP as a corporate attorney focusing on capital markets and mergers and acquisition transactions.

Mr. Hoverman received a B.A. from Yale University, where he graduated cum laude with distinction in history and was a Robert C. Bates Fellow and New Prize recipient, and received a J.D. and M.B.A. from Columbia University, where he was a James Kent Scholar and a John C. Olin Fellow. Mr. Hoverman holds Series 7, 24, 63 and 79 licenses and the designation of Chartered Financial Analyst, and is an inactive member of the New York Bar.


 

Dr. Mitesh J. Borad

 
 

SCIENTIFIC ADVISORY BOARD MEMBER

Dr. Borad is currently an Associate Professor of Medicine at Mayo Clinic College of Medicine and Science. He also serves as the Director of the GI Cancer Cellular, Gene and Virus Therapy lab, Director of the Liver and Biliary Cancer Research Program and Deputy Director, Biomarker Discovery Program at the Center for Individualized Medicine at Mayo Clinic.  Dr. Borad concurrently serves on the National Cancer Institute’s Hepatobiliary Task Force, an appointment he has held since 2011.  Prior to joining Mayo Clinic, he spent three years as a Drug Development Scholar/Genomics Medicine Scholar at the Translational Genomic Research Institute, where he worked closely with world-renowned experts, including Dr. Daniel D. Von Hoff.

He earned his B.S. in Biomedical Engineering (summa cum laude) from Boston University and his M.D. from the University of Medicine and Dentistry of New Jersey.  Subsequently, Dr. Borad obtained his internal medical training at Cedars-Sinai Medical Center and completed his Medical Oncology Fellowship at Tulane University School of Medicine.

Dr. Borad holds a Certification in Medical Oncology from the American Board of Internal Medicine and is a member of more than 20 professional organizations and committees, including presently being seated as Vice Chairman of the International Cholangiocarcinoma Research Network.  Dr. Borad has a long and distinguished list of accolades and accomplishments, such as earning a 2014 New Innovator Award from the National Institute of Health and being named 2011 Paul Calabresi Scholar in Clinical-Translational Research by Mayo Clinic.



Dr. J. Jacques Carter

 

SCIENTIFIC ADVISORY BOARD MEMBER

Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

Dr. Carter completed his residency training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, followed by a graduate program at the Harvard School of Public Health, where he received his MPH degree. He then completed a clinical fellowship in Primary Care Medicine at the Massachusetts General Hospital.

Dr. Carter has held a number of clinical and administrative positions, including Medical Directorships of several local and national health care organizations. A former director of one of the major clerkships, he now serves as a teacher/advisor/mentor for students at Harvard Medical School and the Harvard School of Public Health. Dr. Carter has been active in a number of civic and community organizations, including past president of the board of Family Service of Greater Boston and past chair of the Brookline Advisory Council on Public Health. He regularly gives talks on medical and health related issues to community groups and students throughout greater Boston. He also lectures nationally and internationally on medical and public health topics. Dr. Carter serves as a medical consultant and resource for members of the media. He is a past President of the Harvard School of Public Health Alumni Association and a current director of the Harvard Alumni Association. Dr. Carter is a founding member of the Georgetown University African American Advisory Board. He is the recipient of the 2010 Harvard Medical School/Harvard School of Dental Medicine Community Service Lifetime Achievement Award. His bio has been included in “Who’s Who in the East, “Who’s Who in Medicine and Healthcare”, Who’s Who in Science and Engineering, and “Who’s Who in America”.



OBMP pipeline
 

http://oncbiomune.com/pipeline/
 

¹Upon completion of a successful Phase 1 study, the Company plans to begin a Phase 2 study at Harvard Cancer Centers.

 

Phase 2 clinical trial of ProscaVax for early-stage prostate cancer to be hosted at Beth Israel Deaconess Medical Center a teaching hospital of Harvard University Medical School in Boston, MA.

ProscaVax is OncBioMune’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Per the study protocol, patients to be enrolled will be in what is termed “active surveillance,” a disease management option for patients with localized prostate cancer that elect to work with their doctor to monitor the disease for progression before taking more drastic intervention measures, such as surgery or radiotherapy.  To the Company’s knowledge, the trial of ProscaVax is the first ever worldwide for a prostate cancer vaccine technology addressing the active surveillance patient population.

http://oncbiomune.com/2018/06/20/oncbiomune-to-commence-phase-2-trial-of-proscavax-for-early-stage-prostate-cancer-patients/


Concurrent with the Phase 2 trial of patients in active surveillance, the Company is undergoing the approval process to initiate a Phase 2 trial of ProscaVax in hormone-naïve recurrent prostate cancer patients with increasing PSA at the Urology Clinics of North Texas.

 
 
 

OBMP Daily Chart





 

OBMP Weekly Chart



 

OBMP SECURITY DETAILS

Share Structure

 
Authorized Shares
500,000,000
Outstanding Shares
223,744,842
Restricted
117,530,685
Unrestricted
89,207,059
Held at DTC
89,059,869
Float
9,773,505
https://www.otcmarkets.com/stock/OBMP/security

Last 10-Q

https://www.sec.gov/Archives/edgar/data/1362703/000149315218008916/form10-q.htm
 
 
Contact:
http://oncbiomune.com/
OncBioMune Pharmaceuticals, Inc.
Jonathan Head, Phd
Chief Executive officer and Chairman
Jhead@oncbiomune.com                 Image result for biotech


 

 

OBMP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OBMP News: Quarterly Report (10-q) 05/15/2019 05:44:06 PM
OBMP News: Information Statement - All Other (definitive) (def 14c) 05/13/2019 05:16:12 PM
OBMP News: Current Report Filing (8-k) 05/02/2019 05:02:17 PM
OBMP News: Statement of Changes in Beneficial Ownership (4) 04/30/2019 06:00:54 PM
OBMP News: Statement of Changes in Beneficial Ownership (4) 04/30/2019 06:00:24 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#8292  Sticky Note Title: A Phase 2, Randomized Study of Proscavax, BooDog 03/26/19 11:59:49 AM
#7360  Sticky Note Probably the best written PR I've read from BooDog 11/08/18 11:08:53 AM
#8581   New symbol should be CMIU. learningcurve2020 05/19/19 09:17:05 AM
#8580   Really? southerngent1 05/18/19 03:20:26 PM
#8579   Assuming they know the trials will not move learningcurve2020 05/17/19 06:23:09 PM
#8578   Really? learningcurve2020 05/17/19 09:33:14 AM
#8577   so do you still own any shares in southerngent1 05/17/19 12:36:24 AM
#8576   Too risky this close to br. Start looking learningcurve2020 05/16/19 10:59:12 PM
#8575   Not sure I'm too happy about this. BLUEVOODU 05/16/19 06:58:57 PM
#8574   One would hope that the management and leadership southerngent1 05/16/19 04:48:11 PM
#8573   538 million shares in convertible debt with no learningcurve2020 05/16/19 10:07:45 AM
#8572   burnin about 2.4M shares a month. Hard BooDog 05/16/19 07:43:27 AM
#8571   Looks like day traders playing for 7/10 of learningcurve2020 05/15/19 03:23:55 PM
#8570   And note to self: Still no insider learningcurve2020 05/15/19 10:04:17 AM
#8569   I hear what you're saying but just don't learningcurve2020 05/15/19 09:40:39 AM
#8568   I thought I was making it clear. BooDog 05/15/19 08:44:45 AM
#8567   This Biotech penny market should be closed down learningcurve2020 05/14/19 01:11:40 PM
#8566   And if my coal turns to gold it'll learningcurve2020 05/14/19 12:58:06 PM
#8565   Again READ THE POST! drugmanrx 05/14/19 12:38:07 PM
#8564   Please stop! Common retail have already lost learningcurve2020 05/14/19 12:33:10 PM
#8563   Share holders lose nothing. READ THE POST! drugmanrx 05/14/19 12:15:01 PM
#8562   So you're excusing this destruction of shareholders? Just learningcurve2020 05/14/19 12:08:43 PM
#8561   The potential market world wide for an ovarian drugmanrx 05/14/19 10:30:12 AM
#8560   So what's 5 billion shares. drugmanrx 05/14/19 09:47:45 AM
#8559   Disgusting. It's over before it started. Likely learningcurve2020 05/14/19 09:29:27 AM
#8558   a. increasethe Company’s authorized common stock, BooDog 05/14/19 06:54:47 AM
#8557   The proof is in the pudding. doc063 05/13/19 08:28:07 PM
#8556   I love your optimism! But I still say Tanker12 05/13/19 07:57:44 PM
#8555   No, no, no...Not later than July, in my doc063 05/13/19 06:35:21 PM
#8554   I suspect silver very soon. Just my opinion. doc063 05/13/19 06:31:53 PM
#8553   What is your timing of "soon"? September? southerngent1 05/13/19 05:52:31 PM
#8552   What is your your pps of the breakout ? southerngent1 05/13/19 05:48:53 PM
#8551   It could run up to silver in no doc063 05/13/19 01:08:45 PM
#8550   i like and hope your opinion is right. Tanker12 05/13/19 01:05:05 PM
#8549   Got it all backwards again. Remarkable. learningcurve2020 05/12/19 11:41:32 AM
#8548   Fact #1: "I'm always right." BlackObelisk 05/11/19 08:39:33 PM
#8547   I've been talking to myself since day one learningcurve2020 05/11/19 02:34:17 PM
#8546   I really figured you’d be tired of talking bh585 05/11/19 10:55:38 AM
#8545   A million plus shares traded sideways. Leadership learningcurve2020 05/10/19 07:52:34 PM
#8544   Off to some start this morning! lol Still waiting learningcurve2020 05/10/19 09:34:46 AM
#8543   This stock may take off at any day. doc063 05/09/19 07:20:27 PM
#8542   Yeah, looks like breakout in shares outstanding heading learningcurve2020 05/09/19 01:44:01 PM
#8541   This stock is getting ready for breakout. doc063 05/09/19 01:24:00 PM
#8540   LOL learningcurve2020 05/08/19 10:04:52 PM
#8539   I wish I could be in a position Tanker12 05/08/19 01:32:11 PM
#8538   I don’t think it’s a big deal either way. Tanker12 05/08/19 01:29:48 PM
#8537   Not clear how the company could pr what learningcurve2020 05/07/19 09:47:27 AM
#8535   I consider disclosing shares under ownership as a southerngent1 05/05/19 11:22:35 PM
#8534   As a 2.5 holder (something i wish to Anymouse69 05/04/19 07:03:53 PM
#8533   Mr Southerngent I have often wondered the same frankyahoo 05/04/19 04:50:21 PM
#8532   Key word being 'Supposedly'. Smells like learningcurve2020 05/04/19 01:02:28 PM
#8531   Does all of this need to be posted southerngent1 05/03/19 11:54:27 PM
PostSubject